BioSpace News Archive

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study.

Takeda and Pfizer announced that the German Hodgkin Study Group will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® in combination with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology Annual Meeting and at the 29th European Hematology Association Annual Meeting.

Summit Therapeutics Inc. announced that the Journal of the American Medical Association published a manuscript titled, “Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial.”

ClearPoint Neuro, Inc. announces full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the 2024 Biennial Meeting of the American Society of Stereotactic and Functional Neurosurgery from Saturday, June 1st – Tuesday, June 4th in Nashville.

Werewolf Therapeutics, Inc. announced new clinical data from the Phase 1/1b trial evaluating WTX-124, its conditionally activated Interleukin-2 INDUKINETM molecule, in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy.

Corbus Pharmaceuticals Holdings, Inc., announced , that the Poster [#296] Clinical Update Related to the First-In-Human Trial of SYS6002, A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate, has been presented at American Society of Clinical Oncology Annual Conference by Dr. Jian Zhang, Chief Physician, Deputy Director of Administration, Clinical director of Phase 1 Centre, Fudan University Shanghai Cancer Center.

Cantargia Cantargia gave a presentation at the ASCO conference showing clinical data on nadunolimab counteracting the serious problem of chemotherapy induced neuropathy, an additional positive finding beyond its promising antitumor effects.

Akeso, Inc. announced that, on May 24, 2024, Akeso received marketing authorization in China from the National Medical Products Administration.

TiumBio Co., Ltd. announced interim results from the Phase 1b clinical trial of TU2218 in combination with pembrolizumab at the 2024 American Society of Clinical Oncology Annual Meeting.

Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with pembrolizumab that is well-suited to first-line lung cancer development